{
    "clinical_study": {
        "@rank": "65424", 
        "arm_group": {
            "arm_group_label": "LY2875358", 
            "arm_group_type": "Experimental", 
            "description": "LY2875358 will be administered intravenously (IV) at 2000 milligram (mg) bi-weekly in 28 day Cycle."
        }, 
        "brief_summary": {
            "textblock": "The main purpose of this study is to evaluate the effectiveness of LY2875358 in participants\n      with MET diagnostic positive (+), advanced gastric or gastroesophageal junction (GEJ)\n      cancer."
        }, 
        "brief_title": "A Study of LY2875358 in Participants With MET Positive, Advanced Gastric Cancer", 
        "completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Gastric Cancer", 
        "condition_browse": {
            "mesh_term": "Stomach Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Have a diagnosis of a histopathologically or cytologically confirmed local and/or\n             advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma which is\n             unresectable\n\n          -  Have received 2 regimens of prior chemotherapies for gastric or GEJ adenocarcinoma\n\n          -  Have the presence of measurable disease as defined by the Response Evaluation\n             Criteria in Solid Tumors (RECIST 1.1)\n\n          -  Have consent to provide a tissue sample for pre-screening\n\n          -  Determined to be MET diagnostic positive based upon testing of a tumor sample\n             obtained at any time before enrollment\n\n          -  Have discontinued all previous treatments for cancer, including chemotherapy and\n             radiotherapy, for at least 3 weeks before enrollment and  have recovered from the\n             acute effects of therapy\n\n          -  Have adequate organ function\n\n          -  Male participants: must agree to use a reliable method of birth control and to not\n             donate sperm during the study and for at least 4 months following last dose of study\n             drug or country requirements, whichever is longer\n\n          -  Female participants: are women of child-bearing potential who test negative for\n             pregnancy \u226414 days before enrollment based on a serum pregnancy test and agree to use\n             a reliable method of birth control during the study and for 4 months following the\n             last dose of the study drug and must also not be breastfeeding\n\n          -  Have a performance status of \u22641 on the Eastern Cooperative Oncology Group (ECOG)\n             scale\n\n          -  Have an estimated life expectancy, in the judgment of the investigator, of at least\n             12 weeks\n\n        Exclusion Criteria:\n\n          -  Are currently enrolled in, or discontinued within the last 21 days from, a clinical\n             trial involving an investigational product or non-approved use of a drug or device,\n             or concurrently enrolled in any other type of medical research judged not to be\n             scientifically or medically compatible with this study\n\n          -  Have previously completed or withdrawn from this study or any other study\n             investigating LY2875358\n\n          -  Have an active fungal, bacterial, and/or known viral infection\n\n          -  Have a history of New York Heart Association class \u22653, unstable angina, myocardial\n             infarction (MI) in 6 months prior to study drug administration\n\n          -  Have symptomatic central nervous system (CNS) malignancy or metastasis\n\n          -  Have previous or concurrent malignancies\n\n          -  Have received a liver transplant, or have liver cirrhosis with a Child-Pugh Stage of\n             B or C\n\n          -  Have corrected QT interval (QTc) of >470 millisecond (msec) on screening\n             electrocardiogram (ECG)\n\n          -  Have received previous treatment with any hepatocyte growth  factor (HGF)/MET\n             targeting therapeutics\n\n          -  Have a history of radiation therapy involving more than 25% of the bone marrow.\n             Previous radiation therapy is allowed but should have been limited and must not have\n             included whole pelvis radiation"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "15", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 22, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01874938", 
            "org_study_id": "15007", 
            "secondary_id": "I4C-JE-JTBE"
        }, 
        "intervention": {
            "arm_group_label": "LY2875358", 
            "intervention_name": "LY2875358", 
            "intervention_type": "Biological", 
            "other_name": "Administered IV"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "February 20, 2014", 
        "location": [
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Aichi", 
                        "country": "Japan", 
                        "zip": "4648681"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Chiba", 
                        "country": "Japan", 
                        "zip": "277 8577"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Hokkaido", 
                        "country": "Japan", 
                        "zip": "060"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Hyogo", 
                        "country": "Japan", 
                        "zip": "650-0047"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Osaka", 
                        "country": "Japan", 
                        "zip": "560"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "135 720"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Japan", 
                "Korea, Republic of"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "A Non-Randomized, Open-Label, Single-Arm, Phase 2 Study of LY2875358 in Patients With MET Diagnostic Positive, Advanced Gastric Cancer", 
        "overall_contact": {
            "last_name": "There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or", 
            "phone": "1-317-615-4559"
        }, 
        "overall_official": {
            "affiliation": "Eli Lilly and Company", 
            "last_name": "Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT-5 hours, EST)", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Japan: Ministry of Health, Labor and Welfare", 
                "Japan: Pharmaceuticals and Medical Devices Agency", 
                "South Korea: Korea Food and Drug Administration (KFDA)"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Progression Free Survival (PFS) Rate", 
            "safety_issue": "No", 
            "time_frame": "8 Weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01874938"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Proportion of Participants who Exhibit Confirmed Complete Response (CR) or Partial Response (PR) (Overall Response Rate [ORR])", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Confirmed CR or PR (Estimated up to 4 Months)"
            }, 
            {
                "measure": "Proportion of Participants who Exhibit Stable Disease (SD) or Confirmed CR or PR (Disease Control Rate [DCR])", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Measured Progressive Disease or Death from Any Cause (Estimated up to 4 Months)"
            }, 
            {
                "measure": "Duration of Response", 
                "safety_issue": "No", 
                "time_frame": "Date of CR or PR to Date of Measured Recurrent or Progressive Disease or Death from Any Cause (Estimated up to 4 Months)"
            }, 
            {
                "measure": "Overall Survival (OS)", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Death from Any Cause (Estimated up to 6 Months)"
            }, 
            {
                "measure": "Pharmacokinetics (PK): Systemic Clearance (CL) of LY287358", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Study Completion (Estimated up to 4 Months)"
            }, 
            {
                "measure": "Pharmacokinetics (PK):  Volume of distribution (V) of LY287358", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Study Completion (Estimated up to 4 Months)"
            }, 
            {
                "measure": "PFS", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Measured Progressive Disease or Death from Any Cause (Estimated up to 6 Months)"
            }
        ], 
        "source": "Eli Lilly and Company", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Eli Lilly and Company", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}